Skip to main content

IAVI 011

Phase:
I
Status:
Completed
Strategies:
Viral Vector - Pox
Candidates:
MVA.HIVA
Countries:
South Africa;United Kingdom;Switzerland
Volunteers:
81
Partners:
Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa; HIV Vaccine Research Unit, Medical Research Council (MRC), Durban, South Africa; Simbec Research Limited-Merthyr Tydfil, South Wales, UK; Division of Immunology and Allergy, Lausanne, Switzerland; South African AIDS Vaccine Initiative (SAAVI).

 
Study Summary:
 
Phase I study to evaluate the safety and immunogenicity of a Modified Vaccinia Virus Ankara vaccine containing the clade A HIV-1 gag gene (MVA HIVA) administered by three different routes and at three different dosage levels in healthy volunteers.